Reaction Biology

Reaction Biology is a contract research organization providing a full suite of drug discovery services

Sector Healthcare
Ownership Majority
Date of acquisition 03/2022

Dedicated team

Contact information

www.reactionbiology.com

Address

1 Great Valley Parkway, Suite 2
Malvern, 19355, PA
USA

Founded in 2001, Reaction Biology (“Reaction”) is a contract research organization (CRO) that provides a full suite of drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction’s capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies, and an extensive array of cell-based assays. Reaction maintains one of the largest panels of kinase assays in the world with over 750 unique assays. With over 2,000 validated assays, the company performs more than 5,000 client projects annually across its two facilities in Malvern, PA, and Freiburg, Germany.

Leadership position with growing market share in attractive niche markets

Reaction has consistently generated above-market growth in each of its service areas throughout its history and in particular during the last several years. The company is the largest player (by revenue and breadth of offering) in the kinase assay segment of drug discovery, a market that is growing rapidly driven by a combination of end market growth and a continued trend toward outsourcing. Reaction is growing materially faster than the market in cell-based assays, epigenetic assays and in its other lines of service. Such market share gains are a testament to the company’s scientific leadership, consistently high-quality testing capabilities, and its consistently strong customer service.

Differentiated capabilities promote client satisfaction

Reaction’s proprietary portfolio of 750+ kinase assays is unmatched in the industry. This market leadership bolsters not only its breadth of offering but also its speed of turnaround. Through its proprietary workflow tools and customized equipment, Reaction performs assay runs in with superior data integrity and less waste than alternative methods. This technology further allows Reaction to provide enhanced data for assessing the validity of targeted drug effects. These differentiated capabilities combined with the expertise of Reaction’s scientific talent promote high customer satisfaction and drive repeat business.